MAP4K4 and neoplasm: A recent genomic and proteomic analysis of a cohort of 218 pediatric brain tumors (54) revealed increased levels of MAP4K4, EndoA1, and EndoA3—both at protein and RNA levels—but not of EndoA2, in primary MB and ganglioglioma tumor samples (Fig S4C).